Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

First In Human, Multi-Center Open-Label Randomized Trial to Assess Safety of Rincell-1 Otic Neural Progenitor Cell-Based Therapy and Standard Care vs Standard Care Alone, in Adults With Neural Hearing Loss Eligible for Cochlear Implantation

Next Previous
Trial Profile

First In Human, Multi-Center Open-Label Randomized Trial to Assess Safety of Rincell-1 Otic Neural Progenitor Cell-Based Therapy and Standard Care vs Standard Care Alone, in Adults With Neural Hearing Loss Eligible for Cochlear Implantation

Status: Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 28 Sep 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cell replacements (Primary)
  • Indications Hearing loss; Sensorineural hearing loss
  • Focus Adverse reactions; First in man; Proof of concept
  • Sponsors Rinri Therapeutics

Most Recent Events

  • 09 Jul 2025 New trial record
  • 01 Jul 2025 According to Rinri Therapeutics media release, the company announced the approval of its Clinical Trial Application (CTA) from the UK MHRA for its lead asset Rincell-1.
  • 01 Jul 2025 According to Rinri Therapeutics media release, clinical proof-of-concept data from the trial is expected within 12 months of trial initiation.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top